| Fatal cardiomyopathy associated with pegylated interferon/ribavirin in a patient with chronic hepatitis C. | |
| | |
MedLine Citation:
|
PMID: 16462543 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
We report the case of a 45-year-old man with HCV treated with pegylated interferon-alpha/ribavirin, in whom fatal cardiomyopathy occurred. Cardiomyopathy is a rare complication of high dose of standard interferon but has never been reported with pegylated interferon. The relationship between pegylated interferon-alpha/ribavirin and the development of cardiomyopathy is highly probable for the following reasons: (1) a cardiologist consultation with specific investigations had been performed before treatment excluding a pre-existing cardiomyopathy; (2) symptoms of advanced dilated cardiomyopathy appeared immediately after the end of treatment; (3) other causes of cardiomyopathy have been ruled out. In all except one of the 21 reported cases with standard interferon, cardiomyopathy was reversible. In our patient, fatal cardiomyopathy occurred with a usual dose of pegylated interferon-alpha. Clinicians should be aware of this potential complication when evaluating the ratio benefit/risk of treatment in patients with chronic hepatitis C infection. |
| | |
Authors:
|
Bertrand Condat; Tarik Asselah; David Zanditenas; Bertrande Estampes; Ariel Cohen; Dermot O'Toole; Joëlle Bonnet; Yann Ngo; Patrick Marcellin; Martine Blazquez |
Related Documents
:
|
14663163 - Granulocytic sarcoma of the pancreas. a report of one case and review of the literature. 23659583 - Reviewer acknowledgement 2012. 11316183 - Postinfantile giant cell hepatitis complicating ulcerative colitis: a case report and r... |
Publication Detail:
|
Type: Case Reports; Journal Article; Review |
Journal Detail:
|
Title: European journal of gastroenterology & hepatology Volume: 18 ISSN: 0954-691X ISO Abbreviation: Eur J Gastroenterol Hepatol Publication Date: 2006 Mar |
Date Detail:
|
Created Date: 2006-02-07 Completed Date: 2006-11-14 Revised Date: 2009-10-16 |
Medline Journal Info:
|
Nlm Unique ID: 9000874 Medline TA: Eur J Gastroenterol Hepatol Country: England |
Other Details:
|
Languages: eng Pagination: 287-9 Citation Subset: IM |
Affiliation:
|
Service d'hépato-gastroentérologie, Hôpital Saint-Camille, Bry sur Marne, France. B.Condat@ch-bry.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antiviral Agents
/
administration & dosage,
adverse effects* Cardiomyopathy, Dilated / chemically induced* Drug Administration Schedule Drug Therapy, Combination Fatal Outcome Hepacivirus* Hepatitis C, Chronic / drug therapy* Humans Interferon Alfa-2a / administration & dosage, adverse effects* Male Middle Aged Polyethylene Glycols / administration & dosage, adverse effects* Ribavirin / administration & dosage, adverse effects* |
| Chemical | |
Reg. No./Substance:
|
0/Antiviral Agents; 0/Polyethylene Glycols; 0/peginterferon alfa-2a; 36791-04-5/Ribavirin; 76543-88-9/Interferon Alfa-2a |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Inter-observer variations on interpretation of capsule endoscopies.
Next Document: Resolution of diabetes in type 2 diabetic patient treated with IFN-alpha and ribavirin for hepatitis...